Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpuraMatthieu Jestin, Paul Coppo, Pierre Perez et al.|Blood|2018Cited by 163
Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference CenterY. Benhamou, Lautrette Alexandre, Pierre‐Yves Boëlle et al.|Journal of Thrombosis and Haemostasis|2014Cited by 139
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic PurpuraMélanie Roriz, Paul Coppo, Mickaël Landais et al.|Medicine|2015Cited by 72
Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survivalRenaud Prével, Paul Coppo, Claire Roubaud‐Baudron et al.|Blood|2019Cited by 61
Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? experience of the <scp>F</scp>rench thrombotic microangiopathies reference centerY. Benhamou, Paul Coppo, Jean-Luc Baudel et al.|American Journal of Hematology|2015Cited by 47